a

RTI Biologics Reports $43.7M in Q1 Revenue, 8% Increase Featured

Written by  Laura Miller | April 26, 2012
Social sharing
RTI Biologics reported $43.7 million in first quarter revenues, an 8 percent increase over the same period in 2011.
Reported net income was $2 million for the first quarter, up from $1.2 million last year. The company attributes its success to its direct sports medicine and BGS/GO implants. The company is investing in new product development initiatives and direct distribution this year, which could positively impact future revenue growth.

More Articles on Orthopedic Device Companies:

AlloSource Hires Dale Binke as Vice President of Marketing & Sales

Orthofix Sells Sports Medicine Business for $157.5M

Johnson & Johnson Q1 Orthopedic Sales Flat


© Copyright ASC COMMUNICATIONS 2011. Interested in LINKING to or REPRINTING this content? View our policies here.

blog comments powered by Disqus